同: 脳室内髄膜腫

WordNet

within the system of ventricles in the brain; "intraventricular pressure"
a tumor arising in the meninges which surround the brain and spinal cord; usually slow growing and sometimes malignant

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 髄膜腫：臨床症状および診断 meningioma clinical presentation and diagnosis
2. 脳腫瘍の臨床所見および診断 clinical presentation and diagnosis of brain tumors
3. 良性（WHOのグレードI）髄膜腫の治療 treatment of benign who grade i meningioma
4. 脳室内出血 intraventricular hemorrhage
5. 非定型悪性髄膜腫 atypical and malignant meningiomas

English Journal

Dural arteriovenous fistulas associated with benign meningeal tumors.

Vellimana AK, Daniels DJ, Shah MN, Zipfel GJ, Lanzino G.Author information Department of Neurological Surgery, Washington University School of Medicine, 660 S. Euclid Ave, Campus Box 8057, Saint Louis, MO, 63108, USA, vellimana@gmail.com.AbstractBACKGROUND: Dural arteriovenous fistulas (dAVFs) are usually idiopathic lesions. While individual case reports have documented the occurrence of dAVFs in conjunction with benign meningeal tumors, a detailed characterization of this association is lacking. The objective of this study was to critically examine the relationship between benign meningeal tumors and dAVFs.
Acta neurochirurgica.Acta Neurochir (Wien).2014 Mar;156(3):535-44. doi: 10.1007/s00701-013-1946-z. Epub 2013 Dec 22.
BACKGROUND: Dural arteriovenous fistulas (dAVFs) are usually idiopathic lesions. While individual case reports have documented the occurrence of dAVFs in conjunction with benign meningeal tumors, a detailed characterization of this association is lacking. The objective of this study was to criticall
PMID 24363145

An audit of immunohistochemical marker patterns in meningioma.

Baxter DS1, Orrego A2, Rosenfeld JV3, Mathiesen T4.Author information 1Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institute, R3:02 KS, Stockholm S-17176, Sweden.2Department of Clinical Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden.3Department of Neurosurgery, Alfred Hospital, Monash University, Melbourne, VIC, Australia.4Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institute, R3:02 KS, Stockholm S-17176, Sweden. Electronic address: tiit.mathiesen@karolinska.se.AbstractMeningiomas may express a number of potentially growth-promoting receptors including receptors for progesterone, growth hormone and vascular endothelial growth factor (VEGF). These and other receptors are potential targets for chemotherapy. We have prospectively studied a panel of markers as a routine in order to obtain data of individual expression of markers that may provide targets for anti-receptor treatment. One hundred and seventy-five consecutive patients operated on for meningiomas between 2005 and 2008 were prospectively analysed with antibodies against receptors for growth hormone, insulin-like growth factor 1 (IGF-1), androgen receptors, progesterone receptors (PR) and antibodies against CD34, VEGF, Ki-67 and caspase-3. Expression of IGF-1 receptor (IGF-1r), epidermal growth factor receptor (EGFR) E30 and growth hormone receptor (GHr) was conserved across histological grades and found in 88% to 94% of meningiomas. PR were detected in 87%, but expression decreased in aggressive tumours. Angio-markers such as VEGF and CD34 were detected in 69% and 17% of meningiomas, respectively. Androgen receptors and caspase-3 were uncommon. The analyses of a panel were undertaken as a clinical routine in order to assess its feasibility and to provide data that can be utilised in a clinical setting. Three putative therapeutic receptor targets, IGF-1r, GHr and EGFR E30 were expressed in a large majority of tumours and in contrast to PR maintained expression despite increasing pathological grade of meningioma. Our data also suggest that anti-progesterone therapies and anti-angiogenic therapies could be targeted to subsets of meningioma patients who express PR or have CD34-positive tumours.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia.J Clin Neurosci.2014 Mar;21(3):421-6. doi: 10.1016/j.jocn.2013.06.008. Epub 2013 Nov 11.
Meningiomas may express a number of potentially growth-promoting receptors including receptors for progesterone, growth hormone and vascular endothelial growth factor (VEGF). These and other receptors are potential targets for chemotherapy. We have prospectively studied a panel of markers as a routi
PMID 24231566

Role of external beam radiotherapy in the treatment of relapsing meningioma.

Buglione M, De Bari B, Trevisan F, Ghirardelli P, Pedretti S, Triggiani L, Magrini SM.Author information Radiation Oncology Department, fESTRO, AO Spedali Civili - Istituto del Radio "O. Alberti", Università degli Studi di Brescia, Piazzale Spedali Civili, 1, 25123, Brescia, Italy.AbstractThe role of radiotherapy in the treatment of relapsing meningiomas is not well established. Data of patients treated with radiotherapy for a relapsing meningioma were retrospectively analyzed. Overall survival (OS) was the primary endpoint of the analysis. Local control and acute and late toxicity rates have been also reported. From April 1986 to February 2011, 37 patients with a diagnosis of recurrent meningioma were treated. Median age was 64 years (range 36-79). A total of 18, 10, 5 and 4 patients were affected by relapsing benign, atypical, malignant meningiomas and meningiosarcomas, respectively (WHO classification). Median dose was 60 Gy (range 46-66 Gy). The median follow-up was 42 months (range 3-300 months). OS at 1, 3, 5 and 8 years was 81, 55.6, 43.9 and 25.8 %, respectively (median OS 45 months). A strong statistical trend was observed toward better OS rates in patients treated with radiotherapy at first recurrence compared to those treated at the second (or more) recurrence (OS 50.5 vs. 30.8 %, p = 0.055). A statistical impact of the histology (WHO I vs. II, III and IV) on 5-year OS was also observed (OS 60 vs. 30 %, 0 and 0 %, p = 0.010). Radiotherapy has been well tolerated, with no G2-4 neurological toxicity (RTOG toxicity score). Conventional radiation therapy has an important role in multidisciplinary approach in the treatment of recurrence of meningiomas. The histological type and the timing of the radiotherapy are prognostic factors in terms of survival.
Medical oncology (Northwood, London, England).Med Oncol.2014 Mar;31(3):866. doi: 10.1007/s12032-014-0866-y. Epub 2014 Feb 7.
The role of radiotherapy in the treatment of relapsing meningiomas is not well established. Data of patients treated with radiotherapy for a relapsing meningioma were retrospectively analyzed. Overall survival (OS) was the primary endpoint of the analysis. Local control and acute and late toxicity r
PMID 24504843

Japanese Journal

Pathology: Microcystic meningioma of the fourth ventricle in a dog

Salvadori Claudia,Pintore Maria Domenica,Ricci Emanuele [他]
日本獣醫學会会誌 73(3), 367-370, 2011-03-00
NAID 40018785961

Third Ventricular Meningioma : Case Report

WAJIMA Daisuke,IIDA Junichi,NISHI Noriyuki
Neurologia medico-chirurgica = 神経外科 51(1), 75-78, 2011-01-15
… Intraoperative diagnosis was meningioma. … The histological diagnosis was meningothelial meningioma. … However, total removal was needed in this case of benign meningioma, so the operative strategy and the differential diagnosis before operation is considered to be very important. …
NAID 10028104727

Microcystic Meningioma of the Fourth Ventricle in a Dog

SALVADORI Claudia,PINTORE Maria Domenica,RICCI Emanuele,KONAR Martin,TARTARELLI Chiara Laura,GASPARINETTI Nicola,CANTILE Carlo
Journal of Veterinary Medical Science 73(3), 367-370, 2011
… A diagnosis of intraventricular microcystic meningioma was achieved. … Intraventricular meningiomas in dogs are rarely encountered and reports of meningiomas within the fourth ventricle have not yet been described. … Although choroid plexus tumor is the most frequent neoplasia localized in the fourth ventricle, intraventricular meningioma should be included in the differential diagnoses.<br> …
NAID 130000444256